Search Results for "Arthritis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Arthritis. Results 21 to 30 of 36 total matches.
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
for treatment of
plaque psoriasis and psoriatic arthritis.1
STANDARD TREATMENT ― The tumor necrosis factor ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab was approved earlier for treatment of
plaque psoriasis and psoriatic arthritis.
Rilonacept (Arcalyst) for Recurrent Pericarditis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
arthritis,
has been used off-label for years for treatment of
recurrent pericarditis.
THE DISORDER ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and prevention of further
recurrences in patients ≥12 years old. It is the first drug
to be approved in the US for this indication. Anakinra
(Kineret), an IL-1 receptor antagonist FDA-approved for
treatment of rheumatoid arthritis, has been used off-label
for years for treatment of recurrent pericarditis.
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
arthritis. Arthritis Rheumatol 2019; 71:5.
2. A Menter et al. Joint American Academy of Dermatology ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3 doi:10.58347/tml.2024.1694b | Show Introduction Hide Introduction
Belimumab (Benlysta) for Lupus Nephritis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021 (Issue 1634)
of lupus nephritis. Arthritis
Care Res (Hoboken) 2012; 64:797.
5. M Dall'Era et al. Comparison ...
The B-lymphocyte stimulator (BLyS)-specific inhibitor
belimumab (Benlysta – GSK), which was approved
earlier for treatment of active, autoantibody-positive,
nonrenal, systemic lupus erythematosus (SLE), has
now been approved for use in addition to standard
therapy for treatment of active lupus nephritis in
adults. Belimumab is the first drug to be approved in
the US for treatment of both SLE and lupus nephritis.
An EUA for Anakinra (Kineret) for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis ...
The recombinant interleukin-1 (IL-1) receptor
antagonist anakinra (Kineret – Sobi) has been
granted an FDA Emergency Use Authorization
(EUA) for treatment of hospitalized adults with
confirmed COVID-19 pneumonia who require low- or
high-flow supplemental oxygen, are at risk of
progressing to severe respiratory failure, and are
likely to have elevated plasma levels of soluble
urokinase plasminogen activator receptor (suPAR).
Anakinra has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis. Assays for suPAR are...
Voclosporin (Lupkynis) for Lupus Nephritis
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
.
Arthritis Care Res (Hoboken) 2012; 64:797.
2. M Dall’Era et al. Comparison of standard of care treatment ...
Voclosporin (Lupkynis – Aurinia), an oral calcineurin
inhibitor, has been approved by the FDA for use
in combination with the antimetabolite immunosuppressant
mycophenolate mofetil (Cellcept, and
generics) and a corticosteroid for treatment of adults
with active lupus nephritis. It is the first calcineurin
inhibitor to be approved in the US for this indication.
Tacrolimus (Prograf, and others) and cyclosporine
(Neoral, and others), the other available systemic
calcineurin inhibitors, are approved for prophylaxis of
organ rejection in transplant patients.
Ritlecitinib (Litfulo) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386:316.
12. Inhibitors and inducers of CYP enzymes ...
The FDA has approved ritlecitinib (Litfulo – Pfizer), an
oral JAK and TEC kinase family inhibitor, for treatment
of severe alopecia areata in patients ≥12 years old.
Ritlecitinib is the second oral drug to be approved
in the US for treatment of severe alopecia areata;
baricitinib (Olumiant), a JAK inhibitor, is approved
only for use in adults.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-6 doi:10.58347/tml.2023.1690a | Show Introduction Hide Introduction
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
and
psoriatic arthritis.1
STANDARD TREATMENT — An aminosalicylate such
as mesalamine (Lialda, and others ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately to severely active ulcerative colitis (UC)
in adults. Risankizumab is the first IL-23 antagonist
to be approved for treatment of both CD and UC. It is
also approved for treatment of plaque psoriasis and
psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4 doi:10.58347/tml.2024.1715d | Show Introduction Hide Introduction
Guselkumab (Tremfya) — An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
earlier for treatment of ulcerative colitis (UC),
plaque psoriasis, and psoriatic arthritis.1 The IL-23 ...
The injectable interleukin (IL)-23 antagonist
guselkumab (Tremfya – Janssen Biotech) has now
been approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults; it was
approved earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis. The IL-23
antagonists risankizumab (Skyrizi) and mirikizumab
(Omvoh) and the IL-12/23 antagonist ustekinumab
(Stelara, and biosimilars) are also approved for
treatment of CD.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):92-4 doi:10.58347/tml.2025.1730c | Show Introduction Hide Introduction
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
, vomiting, hemorrhage,
diarrhea, abdominal pain, arthralgia, and arthritis.
Hypoadrenalism, hypothyroidism ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of endogenous
growth hormone in children ≥1 year old who weigh
≥11.5 kg. It is the first once-weekly rhGH product to be
approved in the US; other available rhGH formulations
are administered more frequently.